Exorum, 100 mg

Pharmacodynamics. Oxaliplatin is an antitumor drug belonging to a new class of platinum derivatives in which the platinum atom forms a complex with oxalate and 1,2-diaminocyclohexane. Oxaliplatin exhibits a wide spectrum of cytotoxic action. It also shows activity in vitro and in vivo on various cisplatin-resistant tumor models. In combination with 5-fluorouracil a synergistic cytotoxic effect is observed. The study of the mechanism of action of oxaliplatin confirms the hypothesis that biotransformed, aqueous derivatives of oxaliplatin, interacting with DNA by formation of inter- and intrathecal bridges suppress DNA synthesis, which leads to cytotoxicity and antitumor effect. In vivo oxaliplatin undergoes active biotransformation and is not detected in plasma already by the end of 2-hour administration at the dose of 85 mg/m, at that 15% of administered platinum are in blood, and other 85% are quickly distributed through tissues or excreted with urine. Platinum is bound to plasma albumin and excreted in the urine during the first 48 hours. By the fifth day, about 54% of the total dose is found in the urine and less than 3% in the feces. In renal failure, there is a significant decrease in Cl oxaliplatin from (17.6±2.18) L/h to (9.95±1.91) L/h. The effect of severe renal failure on platinum clearance has not yet been studied.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Contraindications

Side effects

Overdose